Castle Biosciences (CSTL) Gross Margin (2018 - 2026)

Castle Biosciences has disclosed Gross Margin across 9 years of filings, most recently posting 75.46% for Q1 2026.

• Gross Margin for Q1 2026 came in at 75.46%, down 592.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 77.88% (down 405.0% YoY), and the FY2025 annual result was 79.37%, down 250.0% from the prior year.
• Gross Margin came in at 75.46% for Q1 2026 at Castle Biosciences, down from 78.95% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 83.31% in Q2 2024 to a low of 75.17% in Q4 2022.
• The 5-year median for Gross Margin is 78.95% (2025), against an average of 79.04%.
• Across the five-year window, Gross Margin sank 886 bps in 2022 and soared 604 bps in 2023, its largest moves.
• Castle Biosciences' Gross Margin stood at 75.17% in 2022, then grew by 8 bps to 81.21% in 2023, then increased by 0 bps to 81.25% in 2024, then slipped by 3 bps to 78.95% in 2025, then retreated by 4 bps to 75.46% in 2026.
• The last three Gross Margin figures came in at 75.46% (Q1 2026), 78.95% (Q4 2025), and 77.48% (Q3 2025), per Business Quant data.